FDMT Q4 2019 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$427M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-55.2% YoY

Gross Profit

-$10M-508.8% margin

Operating Income

-$16M-802.4% margin

Net Income

-$16M-793.8% margin

EPS (Diluted)

$-1.09

QoQ Revenue Growth

+275.9%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$58M

Total Liabilities

$131M

Stockholders' Equity

-$73M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$5M	-55.2%
Gross Profit	-$10M	-$546,500	-1790.0%
Operating Income	-$16M	-$3M	-543.5%
Net Income	-$16M	-$2M	-638.4%